In vivo instability of PlatensiMycin (cas 835876-32-9) and platencin: Synthesis and biological evaluation of urea- and carbamate-PlatensiMycin (cas 835876-32-9)

Add time:07/16/2019    Source:sciencedirect.com

PlatensiMycin (cas 835876-32-9) (PTM) and platencin (PTN), two natural products and promising drug leads that target bacterial and mammalian fatty acid synthases, are known to have unfavorable pharmacokinetic properties. It is not clear, however, what the metabolic fates of PTM and PTN are and no efforts have been reported to address this key roadblock in the development of these compounds as viable drug options. Here we describe the pharmacokinetics of PTM and PTN, and reveal rapid renal clearance as the primary metabolic liability with three additional sites of chemical liability: (i) amide hydrolysis, (ii) glucuronidation, and (iii) oxidation. We determined that hydrolysis is a viable clearance mechanism in vivo and synthesized two PTM analogues to address in vivo hydrolysis. Urea- and carbamate-PTM analogues showed no detectable hydrolysis in vivo, at the expense of antibacterial activity, with no further improvement in systemic exposure. The antibacterial sulfur-containing analogues PTM D1 and PTM ML14 showed significant decreases in renal clearance. These studies set the stage for continued generation of PTM and PTN analogues in an effort to improve their pharmacokinetics while retaining or improving their biological activities.

We also recommend Trading Suppliers and Manufacturers of PlatensiMycin (cas 835876-32-9). Pls Click Website Link as below: cas 835876-32-9 suppliers

Prev:Antibacterial sulfur-containing PlatensiMycin (cas 835876-32-9) and platencin congeners from Streptomyces platensis SB12029
Next:FT-IR, FT-Raman, surface enhanced Raman scattering and computational study of 2-(p-fluorobenzyl)-6-nitrobenzoxazole)